vbi-2901a
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 5, 2022 (NCT05548439)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
- SARS coronavirusImmunity, active
SARS coronavirus immunity, active
- Middle East respiratory syndrome-related coronavirusImmunity, active
Middle East respiratory syndrome-related coronavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05614245 | Phase 1 | Mar 31, 2023 | University of Ottawa, VBI Vaccines Inc. |
| NCT05548439 | Phase 1 | Oct 5, 2022 | University of Ottawa, VBI Vaccines Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Ottawa | Academic/Hospital | 2 | 0 | 1 | 2022 |
| VBI Vaccines Inc. | For profit | 2 | 2 | 1 | 2022 |
2 organizations
Page 1 / 1